noscript

News and Announcements

Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases

  • Published October 15, 2024 7:42AM UTC
  • Publisher Maan Perez
  • Categories Executive Interviews

Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies.

Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a US$20 billion market) and superior to corticosteroids, but with minimal expected side effects.

This video provides a compelling overview of their research and development efforts, focusing on inflammatory skin disorders, bowel disease, and sepsis, and their impact on global health.

Capital Insights
40-Year Medical Drought Ends: This Aussie Biotech’s Breakthrough Could Save Millions

For four decades, the medical community has waited for a groundbreaking advancement in antibiotics. Now, an Australian biotech company is pioneering the first new class of anti-infectives since the 1980s, offering new hope in the fight against antibiotic resistance. With FDA recognition and substantial government backing, this could be the breakthrough that transforms global healthcare.

Join over 45,000+ sophisticated investors

Join Now